The position statement from cancer and bone societies updates recommendations from 2017 for managing bone loss and fracture risk linked to aromatase inhibitor use in hormone-sensitive breast cancer.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/consensus-bisphosphonates-aromatase-inhibitor-bone-loss-2025a1000rta?src=rss
Author :
Publish date : 2025-10-15 12:39:00
Copyright for syndicated content belongs to the linked Source.
